Biodesix
Biodesix is a Colorado-based diagnostic company that offers services such as lung diagnostics and clinical trial testing for biopharmaceutical companies.
Business Model:
Revenue: $31.3M
Employees: 201-500
Industries / Tags:
Detailed Biodesix Information
Geographic Data
Address: 2970 Wilderness Place
City: Boulder
State: CO
Zip: 80301
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$12M
Raised Total:$300M
Social
Metrics
2,745,407Website Global Rank
5,900Website Monthly Traffic
Twitter Followers
Description
Biodesix is a Colorado-based diagnostic company that offers services such as lung diagnostics and clinical trial testing for biopharmaceutical companies.
Contact Phone:
+18664325930
Contact Email:
Biodesix went public on 10/28/2020 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
10/28/2020
IPO Valuation:
$473M
Ticker Symbol:
BDSX
IPO Price:
$18/share
Amount Raised:
$72M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2009 | Series B | $10M | 1/2014 | Debt Financing | 1 | $20M |
CRG CRG |
8/2008 | Series A | $8M | 11/2022 | Post-IPO Debt | 1 | $50M |
Perceptive Advisors Perceptive Advisors |
4/2013 | Series D | $8.8M | 11/2010 | Series C | $7.1M | 3/2021 | Post-IPO Debt | $30M | 11/2022 | Post-IPO Debt | $30M |
Perceptive Advisors, LLC Perceptive Advisors, LLC |
11/2022 | Post-IPO Equity | $40.3M | 4/2022 | Post-IPO Equity | $11.7M | 10/2020 | Venture Round | $20.9M | 12/2021 | Post-IPO Equity | $16.3M | 10/2018 | Venture Round | $17.5M | 6/2015 | Series E | $11M | 1/2015 | Series E | $12M | 10/2020 | IPO | $72M |
|
3/2022 | Post-IPO Equity | $0 |
Lincoln Park Capital Fund Lincoln Park Capital Fund Lincoln Park Capital Fund Lincoln Park Capital Fund |
5/2017 | Venture Round | $13.2M | 2/2016 | Series F | $22M | 5/2018 | Venture Round | $5.3M | 1/2014 | Series E | $6.1M | 11/2022 | Post-IPO Equity | $40.3M | 8/2012 | Series D | $12M | 7/2011 | Series D | $20M | 12/2013 | Series E | $14.4M | 3/2022 | Post-IPO Equity | 1 | $50M |
Lincoln Park Capital Fund Lincoln Park Capital Fund Lincoln Park Capital Fund Lincoln Park Capital Fund |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 6/2019 | Oncimmune | |
| 7/2018 | Integrated Diagnostics |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
